# A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

> **NCT05947812** · PHASE2 · UNKNOWN · sponsor: **60P Australia Pty Ltd** · enrollment: 148 (estimated)

## Conditions studied

- COVID 19 Disease
- Mild to Moderate COVID 19 Disease
- SARS-CoV-2
- Infectious Disease
- Severe Acute Respiratory Syndrome Coronavirus 2

## Interventions

- **DRUG:** Tafenoquine Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05947812
- **Lead sponsor:** 60P Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2024-04-27
- **Final completion:** 2024-04-27
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947812, "A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05947812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*